An inhibitor with GSK3β and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer's disease.
Liu X, Lai LY, Chen JX, Li X, Wang N, Zhou LJ, Jiang XW, Hu XL, Liu WW, Jiao XM, Qi ZT, Liu WJ, Wu LM, Huang YG, Xu ZH, Zhao QC.
Liu X, et al. Among authors: liu ww, liu wj.
Neuropharmacology. 2023 Jul 1;232:109525. doi: 10.1016/j.neuropharm.2023.109525. Epub 2023 Mar 31.
Neuropharmacology. 2023.
PMID: 37004752